Feed Media Screening for Production Clone of F2N78 Cells

초록

Mammalian-cell-derived expression system has been used as a general platform for the production of various recombinant proteins. Especially, Chinese hamster ovary (CHO) cells are used for the production of most glycoprotein biopharmaceuticals. However, many studies in developing and engineering new cell lines have been progressed due to several drawbacks of CHO cells including the presence of different sugars compared to human glycosylation. A human hybrid cell line named F2N78 was developed by somatic fusion of human embryonic kidney cells (HEK293) and Namalwa (Burkitt’s Lymphoma) cells. F2N78 cell line possesses several advantageous phenotypes such as ease to suspension, high transfection efficacy, EBV genome insertion in chromosome, and human-specific glycosylation. For that reason, this cell line can be used for the production of human therapeutic antibodies or vaccines. In order to enhance the productivity of F2N78 cells, media screening was investigated. In previous study, we investigated media screening to find proper basal media for F2N78 cells. MPC002-1 and Excell293 were selected as basal media. Based on these results, combination between basal media and feed media was attempted to enhance productivity of antibody. Candidates for feed media were D Efficient Feed C AGT, Cellboost5, IS CHO Feed CD XP. Using this combination between Excell293 basal medium and Cellboost5, antibody titer can be increased up to 2 fold.